Layer 1

Teva unclear on which generics affected by Actavis buyout

Teva: A full list of affected generics will be released "in due course"

Teva is unable to confirm how many generics it will take over from Actavis, following its $40.5 billion buyout of the UK manufacturing company.

Teva said its acquisition of Actavis Generics from owner Allergan yesterday (August 2) brings together "two leading generics businesses with complementary strengths".

When asked by C+D which of Actavis's more than 850 product lines would transfer over to its new owner, Teva said a full list will be published “in due course”.

As well as generics, "some" over-the-counter products are also being transferred to Teva, including Sudocrem and Infacol, it said.

"Too soon" for livery changes

It is “too soon” to anticipate any livery changes resulting from the takeover, Teva stressed.

“We are focusing our efforts on integrating the Actavis Generics business into Teva as smoothly as possible, with minimum disruption to our customers and patients,” a spokesperson told C+D.

In order for the deal to go ahead, the European Commission requires Teva to “guarantee continuity of competition” in the UK and Ireland by selling part of the Actavis business. As a result, Actavis's Barnstaple manufacturing plant and "a portfolio of generic molecules" will be sold in the "near future", Teva said.

"The remainder of Allergan's generics business in the UK and Ireland is to be integrated with Teva's," it added. 

What do you make of the deal?

Ben Merriman, Community pharmacist

My understanding would be that individual pharmacies shouldn't lose out too much; any increase in price should be reflected with an increase in reimbursement.  Most fo these lines will be in category M and covered by the guaranteed £800m purchase profit.

However, the NHS will be the one picking up the bill.  Reduced competition means increased prices, as we've seen with debranding of drugs like alimemazine tablets/solution, fludrocortisone tablets, nefopam tablets, phenytoin capsules and trimipramine tablets/capsules.  

Robert Rusk, Business Development Manager

Under this acquisition this will surely add to price surges as competition weakens. Pharmacy will be under further strain and smaller manufacturers will struggle to compete on several molecules. Surely the Monopolies and Mergers Commision should have intervened particularly with the current climate.

Job of the week

Pharmacist Manager
Midlands, Cheshire & Dorset
Salary dependent upon experience